INO
insider transactionsINOVIO PHARMACEUTICALS, INC. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
No open-market buys or sells this period. The trades below are grants, option exercises and gifts, which carry no market price.
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Chief Medical Officer
$0
37.7K sh
Own New
-
Grant·A
Chief Medical Officer
$0
46.9K sh
Own New
-
Exercise·M
Chief Medical Officer
$0
9.4K sh
Own +100%
-
Other·F
Chief Medical Officer
$3.3K
2.7K sh · $1.23
Own -6%
-
Exercise·M
Chief Medical Officer
—
9.4K sh
Own +27%
-
Grant·A
Chief Executive Officer
$0
100.2K sh
Own New
-
Grant·A
Chief Executive Officer
$0
123.8K sh
Own New
-
Exercise·M
Chief Executive Officer
$0
28.3K sh
Own +100%
-
Other·F
Chief Executive Officer
$15.1K
12.3K sh · $1.23
Own -10%
-
Exercise·M
Chief Executive Officer
—
28.3K sh
Own +30%
-
Grant·A
Director
$0
34.2K sh
Own New
-
Grant·A
Director
$0
41.8K sh
Own New
-
Grant·A
Director
$0
34.2K sh
Own New
-
Grant·A
Director
$0
41.8K sh
Own New
-
Grant·A
Director
$0
34.2K sh
Own New
-
Grant·A
Director
$0
41.8K sh
Own New
-
Grant·A
Director
$0
34.2K sh
Own New
-
Grant·A
Director
$0
41.8K sh
Own New
-
Grant·A
Peter Kies KEY
CFO
$0
32.5K sh
Own New
-
Grant·A
Peter Kies KEY
CFO
$0
39.8K sh
Own New
-
Exercise·M
Peter Kies KEY
CFO
$0
8.7K sh
Own +100%
-
Other·F
Peter Kies KEY
CFO
$5.8K
4.7K sh · $1.23
Own -10%
-
Exercise·M
Peter Kies KEY
CFO
—
8.7K sh
Own +22%
-
Grant·A
Director
$0
34.2K sh
Own New
-
Grant·A
Director
$0
41.8K sh
Own New
-
Grant·A
Chief Scientific Officer
$0
27.4K sh
Own New
-
Grant·A
Chief Scientific Officer
$0
34.2K sh
Own New
-
Exercise·M
Chief Scientific Officer
$0
6.0K sh
Own +100%
-
Other·F
Chief Scientific Officer
$2.7K
2.2K sh · $1.23
Own -4%
-
Exercise·M
Chief Scientific Officer
—
6.0K sh
Own +14%
-
Grant·A
Director
$0
34.2K sh
Own New
-
Grant·A
Director
$0
41.8K sh
Own New
-
Exercise·M
Chief Medical Officer
$0
2.4K sh
Own New
-
Other·F
Chief Medical Officer
$884
680 sh · $1.30
Own -2%
-
Exercise·M
Chief Medical Officer
—
2.4K sh
Own +7%
-
Exercise·M
Chief Executive Officer
$0
17.7K sh
Own New
-
Other·F
Chief Executive Officer
$10.0K
7.7K sh · $1.30
Own -8%
-
Exercise·M
Chief Executive Officer
—
17.7K sh
Own +21%
-
Exercise·M
Peter Kies KEY
CFO
$0
4.8K sh
Own New
-
Other·F
Peter Kies KEY
CFO
$3.3K
2.6K sh · $1.30
Own -6%
-
Exercise·M
Peter Kies KEY
CFO
—
4.8K sh
Own +13%
-
Exercise·M
Chief Scientific Officer
$0
4.8K sh
Own New
-
Other·F
Chief Scientific Officer
$2.2K
1.7K sh · $1.30
Own -4%
-
Exercise·M
Chief Scientific Officer
—
4.8K sh
Own +12%
-
Exercise·M
Chief Medical Officer
$0
4.3K sh
Own New
-
Other·F
Chief Medical Officer
$2.1K
1.2K sh · $1.74
Own -4%
-
Exercise·M
Chief Medical Officer
—
4.3K sh
Own +14%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 20, 2026 | Michael John Sumner | Grant A | 37.7K | $0 |
| May 20, 2026 | Michael John Sumner | Grant A | 46.9K | $0 |
| May 20, 2026 | Michael John Sumner | Exercise M | 9.4K | $0 |
| May 20, 2026 | Michael John Sumner | Other F | 2.7K | $3.3K |
| May 20, 2026 | Michael John Sumner | Exercise M | 9.4K | — |
| May 20, 2026 | Jacqueline Elizabeth Shea KEY | Grant A | 100.2K | $0 |
| May 20, 2026 | Jacqueline Elizabeth Shea KEY | Grant A | 123.8K | $0 |
| May 20, 2026 | Jacqueline Elizabeth Shea KEY | Exercise M | 28.3K | $0 |
| May 20, 2026 | Jacqueline Elizabeth Shea KEY | Other F | 12.3K | $15.1K |
| May 20, 2026 | Jacqueline Elizabeth Shea KEY | Exercise M | 28.3K | — |
| May 20, 2026 | Ann Calby Miller | Grant A | 34.2K | $0 |
| May 20, 2026 | Ann Calby Miller | Grant A | 41.8K | $0 |
| May 20, 2026 | David B. Weiner | Grant A | 34.2K | $0 |
| May 20, 2026 | David B. Weiner | Grant A | 41.8K | $0 |
| May 20, 2026 | Jay Shepard | Grant A | 34.2K | $0 |
| May 20, 2026 | Jay Shepard | Grant A | 41.8K | $0 |
| May 20, 2026 | Lota S. Zoth | Grant A | 34.2K | $0 |
| May 20, 2026 | Lota S. Zoth | Grant A | 41.8K | $0 |
| May 20, 2026 | Peter Kies KEY | Grant A | 32.5K | $0 |
| May 20, 2026 | Peter Kies KEY | Grant A | 39.8K | $0 |
| May 20, 2026 | Peter Kies KEY | Exercise M | 8.7K | $0 |
| May 20, 2026 | Peter Kies KEY | Other F | 4.7K | $5.8K |
| May 20, 2026 | Peter Kies KEY | Exercise M | 8.7K | — |
| May 20, 2026 | Wendy L Yarno | Grant A | 34.2K | $0 |
| May 20, 2026 | Wendy L Yarno | Grant A | 41.8K | $0 |
| May 20, 2026 | Laurent Humeau | Grant A | 27.4K | $0 |
| May 20, 2026 | Laurent Humeau | Grant A | 34.2K | $0 |
| May 20, 2026 | Laurent Humeau | Exercise M | 6.0K | $0 |
| May 20, 2026 | Laurent Humeau | Other F | 2.2K | $2.7K |
| May 20, 2026 | Laurent Humeau | Exercise M | 6.0K | — |
| May 20, 2026 | Simon X Benito | Grant A | 34.2K | $0 |
| May 20, 2026 | Simon X Benito | Grant A | 41.8K | $0 |
| May 15, 2026 | Michael John Sumner | Exercise M | 2.4K | $0 |
| May 15, 2026 | Michael John Sumner | Other F | 680 | $884 |
| May 15, 2026 | Michael John Sumner | Exercise M | 2.4K | — |
| May 15, 2026 | Jacqueline Elizabeth Shea KEY | Exercise M | 17.7K | $0 |
| May 15, 2026 | Jacqueline Elizabeth Shea KEY | Other F | 7.7K | $10.0K |
| May 15, 2026 | Jacqueline Elizabeth Shea KEY | Exercise M | 17.7K | — |
| May 15, 2026 | Peter Kies KEY | Exercise M | 4.8K | $0 |
| May 15, 2026 | Peter Kies KEY | Other F | 2.6K | $3.3K |
| May 15, 2026 | Peter Kies KEY | Exercise M | 4.8K | — |
| May 15, 2026 | Laurent Humeau | Exercise M | 4.8K | $0 |
| May 15, 2026 | Laurent Humeau | Other F | 1.7K | $2.2K |
| May 15, 2026 | Laurent Humeau | Exercise M | 4.8K | — |
| Mar 31, 2026 | Michael John Sumner | Exercise M | 4.3K | $0 |
| Mar 31, 2026 | Michael John Sumner | Other F | 1.2K | $2.1K |
| Mar 31, 2026 | Michael John Sumner | Exercise M | 4.3K | — |
About INO insider trading
This page tracks insider transactions for INOVIO PHARMACEUTICALS, INC. (INO) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.